1
|
Vlooswijk C, Oerlemans S, Ezendam NPM, Schep G, Slot S, Thong MSY, Vissers PAJ, Beijer S. Physical Activity is Associated with Health Related Quality of Life in Lymphoma Survivors Regardless of Body Mass Index; Results from the Profiles Registry. Nutr Cancer 2021; 74:158-167. [PMID: 33554640 DOI: 10.1080/01635581.2021.1881570] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND Being obese and having a sedentary lifestyle is associated with impaired health-related quality of life (HRQoL) among cancer survivors. The aim of the present study is to investigate the combined influence of body mass index (BMI) and physical activity on HRQoL in lymphoma survivors. METHODS Lymphoma survivors diagnosed between 1999 and 2012 were invited to complete questionnaires about body height and weight, physical activity and HRQoL using the EORTC QLQ-C30. Multivariable analyses were conducted to evaluate the association of BMI and physical activity on HRQoL. RESULTS 1.339 lymphoma survivors responded (response rate of 72%) of whom 43% had a healthy weight, 41% were overweight and 14% were obese. They spent on average 10 h, on moderate to vigorous physical activity (MVPA) per week. Multivariable linear regression analysis shows that relatively high active survivors reported higher HRQoL scores and less fatigue compared to relatively low active lymphoma survivors, regardless of BMI. CONCLUSION MVPA was associated with higher HRQoL in lymphoma survivors regardless of BMI. Further studies, are needed to investigate effects of healthy lifestyle changes to improve HRQoL in lymphoma survivors. Research in understanding association of lifestyle factors may guide future support for lymphoma cancer survivors.
Collapse
Affiliation(s)
- Carla Vlooswijk
- Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| | - Simone Oerlemans
- Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| | - Nicole P M Ezendam
- Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.,CoRPS - Center of Research on Psychology in Somatic diseases, Department of Medical and Clinical psychology, Tilburg University, Tilburg, The Netherlands
| | - Goof Schep
- Department of Sports Medicine, Maxima Medical Center, Veldhoven, The Netherlands
| | - Stefanie Slot
- Department of Hematology, UMC, location VUmc, Amsterdam, The Netherlands
| | - Melissa S Y Thong
- Department of Medical Psychology, Amsterdam University Medical Centers (location AMC), Amsterdam, The Netherlands
| | - Pauline A J Vissers
- Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| | - Sandra Beijer
- Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| |
Collapse
|
2
|
Desai SH, Al-Shbool G, Desale S, Veis J, Malkovska V. Lymphoma survivors have an increased long-term risk of chronic kidney disease. Leuk Lymphoma 2020; 61:2923-2930. [PMID: 32654590 DOI: 10.1080/10428194.2020.1786555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
With improving lymphoma survival, late effects of therapy have emerged. Here, we describe pattern of long-term chronic kidney disease (CKD) in lymphoma survivors. Demographics, comorbidities, lymphoma histology, treatment, and outcome were recorded. Glomerular filtration rate (GFR) was recorded at diagnosis, 1, 2, 5, and 10 years. Rate of GFR decline with time and CKD-free survival were recorded. In 397 patients, median age was 55.3 (18-88), 54% were male, 60% were African Americans, 42% had hypertension (HTN), 15% had DM, 13% had hyperuricemia, 86% received chemotherapy, and 14% had baseline CKD. Total 125 (31%) patients developed CKD in 10 years after lymphoma diagnosis. Probability of CKD development increased significantly with time (23% at 1 year to 41% at 10 years). Rate of GFR decline was 4.6 mL/min/per year. Age, HTN, hyperuricemia, and DM (in young patients) predicted risk of CKD. Thus, lymphoma survivors are at substantial long-term risk of CKD development.
Collapse
Affiliation(s)
| | | | - Sameer Desale
- Medstar Health Research Institute, Hyattsville, MD, USA
| | - Judith Veis
- Medstar Washington Hospital Center, Washington, DC, USA
| | | |
Collapse
|
3
|
Williams AM, Baran AM, Schaffer M, Bushart J, Rich L, Moore J, Barr PM, Zent CS. Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy. Am J Hematol 2020; 95:E16-E18. [PMID: 31621100 DOI: 10.1002/ajh.25663] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2019] [Accepted: 10/11/2019] [Indexed: 11/08/2022]
Affiliation(s)
- AnnaLynn M. Williams
- University of Rochester Medical CenterJames P. Wilmot Cancer Institute Rochester New York
| | - Andrea M. Baran
- University of Rochester Medical CenterJames P. Wilmot Cancer Institute Rochester New York
| | - Mahlon Schaffer
- University of Rochester Medical CenterJames P. Wilmot Cancer Institute Rochester New York
| | - Jocelyn Bushart
- University of Rochester Medical CenterJames P. Wilmot Cancer Institute Rochester New York
| | - Lynn Rich
- University of Rochester Medical CenterJames P. Wilmot Cancer Institute Rochester New York
| | - Jeremiah Moore
- University of Rochester Medical CenterJames P. Wilmot Cancer Institute Rochester New York
| | - Paul M. Barr
- University of Rochester Medical CenterJames P. Wilmot Cancer Institute Rochester New York
| | - Clive S. Zent
- University of Rochester Medical CenterJames P. Wilmot Cancer Institute Rochester New York
| |
Collapse
|
4
|
Trujillo EB, Dixon SW, Claghorn K, Levin RM, Mills JB, Spees CK. Closing the Gap in Nutrition Care at Outpatient Cancer Centers: Ongoing Initiatives of the Oncology Nutrition Dietetic Practice Group. J Acad Nutr Diet 2019; 118:749-760. [PMID: 29576094 DOI: 10.1016/j.jand.2018.02.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Indexed: 12/16/2022]
|
5
|
Ben-Yakov G, Alao H, Haydek JP, Fryzek N, Cho MH, Hemmati M, Samala V, Shovlin M, Dunleavy K, Wilson W, Jones EC, Rotman Y. Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. Hepatol Commun 2019; 3:220-226. [PMID: 30766960 PMCID: PMC6357828 DOI: 10.1002/hep4.1304] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Accepted: 12/01/2018] [Indexed: 12/17/2022] Open
Abstract
Nonalcoholic fatty liver disease is the most common liver disorder in the developed world. Although typically reflecting caloric overload, it can also be secondary to drug toxicity. We aimed to describe the incidence and risk factors for de novo steatosis during chemotherapy for non‐Hodgkin lymphoma (NHL). In this retrospective case‐control study, adult patients with NHL were treated with rituximab, cyclophosphamide, doxorubicin, prednisone, and vincristine (R‐CHOP) or R‐CHOP + etoposide (EPOCH‐R). Patients with liver disease or steatosis were excluded. Abdominal computed tomography was performed pretreatment and at 3‐ to 6‐month intervals and reviewed for steatosis. Patients with de novo steatosis were matched 1:1 to controls by age, sex, and ethnicity. Of 251 treated patients (median follow‐up 53 months), 25 (10%) developed de novo steatosis, with the vast majority (23 of 25; 92%) developing it after chemotherapy. Of those, 14 (61%) developed steatosis within the first 18 months posttreatment and 20 (87%) within 36 months. Cases had higher baseline body mass index (BMI; mean ± SD, 29.0 ± 6.5 versus 26.0 ± 5.2 kg/m2; P = 0.014) and hyperlipidemia (12% versus 2%; P = 0.035). Although their weights did not change during chemotherapy, BMI in cases increased by 2.4 ± 2 kg/m2 (mean ± SD) from end of treatment to steatosis compared to 0.68 ± 1.4 in controls (P = 0.003). Etoposide‐containing regimens were associated with a shorter time to steatosis (median 34 weeks versus 154 weeks; P < 0.001) despite similar baseline risk factors. Conclusion: The recovery period from NHL chemotherapy appears to be a “hot spot” for development of fatty liver, driven by early posttreatment weight gain, especially in subjects with baseline risk factors.
Collapse
Affiliation(s)
- Gil Ben-Yakov
- Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD
| | - Hawwa Alao
- Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD.,Department of Gastroenterology Louis Stokes VA Medical Center Cleveland OH
| | - John P Haydek
- Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD
| | - Nancy Fryzek
- Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD
| | - Min Ho Cho
- Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD.,Department of Medicine MedStar Washington Hospital Center Washington DC
| | - Mehdi Hemmati
- Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD.,Department of Medicine MedStar Health Baltimore MD
| | - Vikram Samala
- Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD
| | - Margaret Shovlin
- Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda MD
| | - Kieron Dunleavy
- Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda MD
| | - Wyndham Wilson
- Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda MD
| | - Elizabeth C Jones
- Radiology and Imaging Sciences National Institutes of Health Clinical Center Bethesda MD
| | - Yaron Rotman
- Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD
| |
Collapse
|
6
|
Hackett F, Dowling M. Lymphoma survivors’ experiences at the end of treatment. J Clin Nurs 2018; 28:400-409. [DOI: 10.1111/jocn.14658] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Revised: 08/21/2018] [Accepted: 08/30/2018] [Indexed: 12/20/2022]
Affiliation(s)
- Fidelma Hackett
- UL Hospitals Group University Hospital Limerick Dooradoyle, Limerick Ireland
| | - Maura Dowling
- School of Nursing and Midwifery National University of Ireland Galway Ireland
| |
Collapse
|
7
|
Xiao DY, Luo S, O'Brian K, Liu W, Carson KR. Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy. Leuk Lymphoma 2016; 58:851-858. [PMID: 27669828 DOI: 10.1080/10428194.2016.1217526] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Understanding weight change patterns in follicular lymphoma (FL) may be important for the assessment of prognosis as well as the long-term care of survivors. A retrospective cohort of United States veterans with a new diagnosis of FL between October 1, 1998 and September 30, 2010 was assembled. Weight changes were evaluated before, during, and after treatment in 896 FL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab (CHOP ± R); cyclophosphamide, vincristine, and prednisone, with or without rituximab (CVP ± R); or rituximab monotherapy. Weight decreased an average of 1.4 kg during therapy, and >5% weight loss during this time period was associated with worse overall survival. Weight increased to an average of 1.4 kg above baseline by 24 months after treatment initiation, with 15% gaining greater than 10% of their baseline weight. Weight management strategies may be an important part of long-term survivorship planning.
Collapse
Affiliation(s)
- Daphne Y Xiao
- a Research Service , St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.,b Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA
| | - Suhong Luo
- a Research Service , St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.,c Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA
| | - Katiuscia O'Brian
- a Research Service , St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.,c Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA
| | - Weijian Liu
- a Research Service , St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA
| | - Kenneth R Carson
- a Research Service , St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.,c Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA.,d Division of Public Health Sciences, Department of Surgery , Washington University School of Medicine , St. Louis , MO , USA
| |
Collapse
|
8
|
O'Brian K, Luo S, Ganti A, Riedell P, Lynch RC, Roop R, Sanfilippo KM, Liu W, Colditz GA, Carson KR. Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leuk Lymphoma 2015; 57:313-319. [PMID: 26085202 DOI: 10.3109/10428194.2015.1056183] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Identifying weight changes associated with treatment of diffuse large B-cell lymphoma (DLBCL) has the potential to improve the long-term health of survivors. A retrospective cohort of United States veterans with a new diagnosis of DLBCL between October 1, 1998 and September 30, 2008, with follow-up until April 23, 2013, was assembled. Weight changes were evaluated before, during, and after treatment in 1935 DLBCL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab (CHOP+/- R). One year prior to treatment, 79% of patients were obese or overweight. During the 12 months leading up to treatment, 57% of the cohort lost weight. Among patients surviving 24 months after treatment initiation, weight increased an average of 2.9 kg above weight at treatment completion. The weight change trends observed in these DLBCL patients suggest that weight management strategies may be an important part of long-term survivorship planning after conclusion of treatment.
Collapse
Affiliation(s)
- Katiuscia O'Brian
- a Research Service, St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.,b Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA
| | - Suhong Luo
- a Research Service, St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.,b Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA
| | - Arun Ganti
- c Department of Emergency Medicine , University of Michigan Health System , Ann Arbor , MI , USA
| | - Peter Riedell
- b Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA
| | - Ryan C Lynch
- d Division of Oncology, Department of Medicine , Stanford University School of Medicine/Stanford Cancer Institute , Stanford , CA , USA
| | - Ryan Roop
- e Northwest Oncology and Hematology, Kalispell Regional Medical Center , Kalispell , MT , USA
| | - Kristen M Sanfilippo
- a Research Service, St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.,b Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA
| | - Weijian Liu
- a Research Service, St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA
| | - Graham A Colditz
- f Division of Public Health Sciences, Department of Surgery , Washington University School of Medicine , St. Louis , MO , USA
| | - Kenneth R Carson
- a Research Service, St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.,b Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA.,f Division of Public Health Sciences, Department of Surgery , Washington University School of Medicine , St. Louis , MO , USA
| |
Collapse
|
9
|
Abstract
Unfavorable physiological, biological, and behavioral alterations during and following treatment for cancer may lead to chronic energy imbalance predisposing to a myriad of deleterious health conditions including obesity, dyslipidemia, and the metabolic syndrome. In addition to the cardiovascular and musculoskeletal effects of these conditions, energy imbalance and metabolic changes after cancer treatment can also affect cancer-related morbidity and mortality. To this end, lifestyle interventions such as diet and physical activity are especially relevant to mitigate the deleterious impact of chronic energy imbalance in cancer survivors.
Collapse
Affiliation(s)
- Emily S Tonorezos
- Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York NY.
| | | |
Collapse
|
10
|
Vecchio L, Seke Etet PF, Kipanyula MJ, Krampera M, Nwabo Kamdje AH. Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: what can be learned from hematologic malignancies? Biochim Biophys Acta Rev Cancer 2013; 1836:90-104. [PMID: 23603458 DOI: 10.1016/j.bbcan.2013.04.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Revised: 01/25/2013] [Accepted: 04/10/2013] [Indexed: 02/06/2023]
Abstract
Epigenetic alterations represent a key cancer hallmark, even in hematologic malignancies (HMs) or blood cancers, whose clinical features display a high inter-individual variability. Evidence accumulated in recent years indicates that inactivating DNA hypermethylation preferentially targets the subset of polycomb group (PcG) genes that are regulators of developmental processes. Conversely, activating DNA hypomethylation targets oncogenic signaling pathway genes, but outcomes of both events lead in the overexpression of oncogenic signaling pathways that contribute to the stem-like state of cancer cells. On the basis of recent evidence from population-based, clinical and experimental studies, we hypothesize that factors associated with risk for developing a HM, such as metabolic syndrome and chronic inflammation, trigger epigenetic mechanisms to increase the transcriptional expression of oncogenes and activate oncogenic signaling pathways. Among others, signaling pathways associated with such risk factors include pro-inflammatory nuclear factor κB (NF-κB), and mitogenic, growth, and survival Janus kinase (JAK) intracellular non-receptor tyrosine kinase-triggered pathways, which include signaling pathways such as transducer and activator of transcription (STAT), Ras GTPases/mitogen-activated protein kinases (MAPKs)/extracellular signal-related kinases (ERKs), phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), and β-catenin pathways. Recent findings on epigenetic mechanisms at work in HMs and their importance in the etiology and pathogenesis of these diseases are herein summarized and discussed. Furthermore, the role of epigenetic processes in the determination of biological identity, the consequences for interindividual variability in disease clinical profile, and the potential of epigenetic drugs in HMs are also considered.
Collapse
Affiliation(s)
- Lorella Vecchio
- Laboratory of Cytometry, Institute of Molecular Genetics, CNR, University of Pavia, 27100 Pavia, Italy
| | | | | | | | | |
Collapse
|
11
|
Jones JA. Weight gain after lymphoma treatment: fat or fiction? Leuk Lymphoma 2012; 53:517-8. [DOI: 10.3109/10428194.2011.644790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|